Pulmonary arterial hypertension associated with connective tissue disease: Meta-analysis of clinical trials

BMJ Open

Volumn 3, Issue 8, 2013, Pages

  Kuwana, Masataka ^a   Watanabe, Hiroshi ^b   Matsuoka, Nobushige ^c   Sugiyama, Naonobu ^c  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMBRISENTAN; BERAPROST; BOSENTAN; ILOPROST; PLACEBO; PROSTACYCLIN; SILDENAFIL; TADALAFIL; TREPROSTINIL;

ARTICLE; BIOSIS; CLINICAL STUDY; CLINICAL TRIAL (TOPIC); CONNECTIVE TISSUE DISEASE; DISEASE ASSOCIATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; EMBASE; EXERCISE; HUMAN; MEDLINE; META ANALYSIS; PROGNOSIS; PULMONARY HYPERTENSION; SENSITIVITY ANALYSIS; WALKING;

EID: 84885354011     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2013-003113     Document Type: Article

References (51)

1. Badesch DB, Champion HC, Sanchez M.A., et al Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2009;54:S55-66.
2. Simonneau G, Robbins IM, Beghetti M, et al Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009;54: S43-54.
3. Condliffe R, Kiely DG, Peacock A.J., et al Connective tissue disease-associated pulmonary hypertension in the modern treatment era. Am J Respir Crit Care Med 2009;179:151-7.
4. Chung L, Liu J, Parsons L., et al Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest 2010;138:1383-94.
5. Hachulla E, Gressin V, Guilevin L., et al Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 2005;52:3792-800. (Pubitemid 41798217)
6. Mukerjee D, St George D, Coleiro B, et al Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 2003;62:1088-93. (Pubitemid 37323574)
7. Kawut SM, Taichman DB, Archer-Chicko CL, et al Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 2003;123:344-50. (Pubitemid 36269414)
8. Avouac J, Wipff J, Kahan A., et al Effects of oral treatments on exercise capacity in systemic sclerosis related pulmonary arterial hypertension: a meta-analysis of randomised controlled trials. Ann Rheum Dis 2008;67:808-14. (Pubitemid 351829381)
9. Galiè N, Manes A, Negro L, et al. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J 2009;30:394-403.
10. Galiè N, Palazzini M, Manes A. Pulmonary arterial hypertension: from the kingdom of the near-dead to multiple clinical trial meta-analyses. Eur Heart J 2010;31:2080-6.
11. Macchia A, Marchioli R, Tognoni G., et al Systematic review of trials using vasodilators in pulmonary arterial hypertension: why a new approach is needed. Am Heart J 2010;159:245-57.
12. He B, Zhang F, Li X., et al Meta-analysis of randomized controlled trials on treatment of pulmonary arterial hypertension. Circ J 2010;74:1458-64.
13. Ryerson CJ, Nayar S, Swiston J.R., et al Pharmacotherapy in pulmonary arterial hypertension: a systematic review and meta-analysis. Respir Res 2010;11:12.
14. McLaughlin VV, Badesch DB, Delcroix M, et al End points and clinical trial design in pulmonary arterial hypertension. J Am Coll Cardiol 2009;54:S97-107.
15. Galiè N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005;353:2148-57. (Pubitemid 41653106)
16. Singh TP, Rohit M, Grover A., et al A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension. Am Heart J 2006;151:851.e1-5.
17. Simonneau G, Rubin LJ, Galiè N, et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 2008;149:521-30.
18. Galiè N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009;119:2894-903.
19. Channick RN, Simonneau G, Sitbon O., et al Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001;358:1119-23. (Pubitemid 32971843)
20. Rubin LJ, Badesch DB, Barst R.J., et al Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903. (Pubitemid 34984638)
21. Galiè N, Beghetti M, Gatzoulis MA, et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 2006;114:48-54. (Pubitemid 44305274)
22. Galiè N, Rubin LJ, Hoeper M, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 2008;371:2093-100. (Pubitemid 351902178)
23. Galiè N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008;117:3010-19.
24. Rubin LJ, Mendoza J, Hood M., et al Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med 1990;112:485-91. (Pubitemid 20100285)
25. Barst RJ, Rubin LJ, Long W.A., et al A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996;334:296-302.
26. Badesch DB, Tapson VF, McGoon M.D., et al Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000;132:425-34. (Pubitemid 30149039)
27. Galiè N, Humbert M, Vachiéry JL, et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2002;39:1496-502.
28. McLaughlin VV, Oudiz RJ, Frost A, et al Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 2006;174:1257-63. (Pubitemid 44924827)
29. Hoeper MM, Leuchte H, Halank M., et al Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2006;28:691-4. (Pubitemid 46331988)
30. Simonneau G, Barst RJ, Galiè N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165:800-4. (Pubitemid 34229650)
31. McLaughlin VV, Gaine SP, Barst R.J., et al Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension. J Cardiovasc Pharmacol 2003;41:293-9. (Pubitemid 36135255)
32. McLaughlin VV, Benza RL, Rubin L.J., et al Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2010;55:1915-22.
33. Hiremath J, Thanikachalam S, Parikh K., et al Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial. J Heart Lung Transplant 2010;29:137-49.
34. Badesch DB, Hill NS, Burgess G, et al Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. J Rheumatol 2007;34:2417-22. (Pubitemid 350230665)
35. Denton CP, Humbert M, Rubin L., et al Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis 2006;65:1336-40. (Pubitemid 44620443)
36. Launay D, Sitbon O, Le Pavec J, et al Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil. Rheumatology 2010;49:490-500.
37. Badesch DB. Ambrisentan therapy for pulmonary arterial hypertension: a comparison by PAH etiology. Chest 2007; 132(Meeting Abstract):488b-489.
38. Badesch DB, Feldman J, Keogh A., et al ARIES-3: ambrisentan therapy in a diverse population of patients with pulmonary hypertension. Cardiovasc Ther 2012;30:93-9.
39. Kunieda T, Nakanishi N, Matsubara H., et al Effects of long-acting beraprost sodium (TRK-100STP) in Japanese patients with pulmonary arterial hypertension. Int Heart J 2009;50:513-29.
40. Oudiz R, Schilz RJ, Barst R.J., et al. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. Chest 2004;126:420-7. (Pubitemid 39093426)
41. Clements PJ, Tan M, McLaughlin V.V., et al The pulmonary arterial hypertension quality enhancement research initiative: comparison of patients with idiopathic PAH to patients with systemic sclerosis-associated PAH. Ann Rheum Dis 2012;71:249-52.
42. Avouac J, Kowal-Bielecka O, Pittrow D., et al; EPOSS Group. Validation of the 6 min walk test according to the OMERACT filter: a systematic literature review by the EPOSS-OMERACT group. Ann Rheum Dis 2010;69:1360-3.
43. Ahmed I, Sutton AJ, Riley RD Assessment of publication bias, selection bias, and unavailable data in meta-analyses using individual participant data: a database survey. BMJ 2012;344: d7762.
44. Naeije R. The 6-min walk distance in pulmonary arterial hypertension: "Je t'aime, moi non plus,". Chest 2010;137:1258-60.
45. Benza RL, Miller DP, Gomberg-Maitland M, et al Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 2010;122:164-72.
46. Miyamoto S, Nagaya N, Satoh T., et al Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 2000;161:487-92. (Pubitemid 30129457)
47. Sitbon O, Humbert M, Nunes H., et al Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002;40:780-8. (Pubitemid 34925627)
48. Groepenhoff H, Vonk-Noordegraaf A, Boonstra A., et al Exercise testing to estimate survival in pulmonary hypertension. Med Sci Sports Exerc 2008;40:1725-32.
49. Humbert M, Sitbon O, Chaouat A., et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010;122:156-63.
50. Humbert M, Sitbon O, Yaïci A, et al Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J 2010;36:549-55.
51. Gilbert C, Brown MC, Cappelleri JC, et al. Estimating a minimally important difference in pulmonary arterial hypertension following treatment with sildenafil. Chest 2009;135:137-42.